3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Ovarian Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
SCLC, Extensive Stage
1
Prostatic Neoplasms
1
Glioblastoma
1
Fludzoparib" and Anti-angiogenic
1
Advanced Solid Tumors
1
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
1
Interventions
pembrolizumab
96
Carboplatin
67
Paclitaxel
56
Cyclophosphamide
40
Capecitabine
30
Specimen Handling
28
sacituzumab govitecan
25
130-nm albumin-bound paclitaxel
24
Gemcitabine
22
Magnetic Resonance Spectroscopy
21
Doxorubicin
20
olaparib
19
Taxes
19
Biopsy
19
Albumin-Bound Paclitaxel
19
Drug Therapy
16
atezolizumab
13
Nivolumab
13
toripalimab
12
Radiotherapy
12
Epirubicin
12
durvalumab
11
Docetaxel
10
Cisplatin
10
Bevacizumab
10
eribulin
9
fludarabine
8
Standard of Care
7
Radiation
7
Injections
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
fluzoparib
×
1 year
×
Clear all
NCT05582499
2026-05-28
FASCINATE-N
Fudan University
Phase 2
Recruiting
716 enrolled